This suggests that ER status is a critical factor that affects the levels of PD-1/PD-L1 in breast cancer tissues, whereas the HER2 status or Ki67 expression level do not seem to affect changes in the expression of PD-1/PD-L1. This evidence concerns the gene ERBB2 and breast carcinoma.